Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Ameren is pitching a regulated-utility growth story built on $31.8 billion of 2026-2030 infrastructure investment, but the thesis has to clear rate cases, customer bills, equity funding, and large-load demand.
Momentus says its cash position has jumped to about $76 million with no debt. The real question is whether Vigoride progress can become revenue before share-count math absorbs the upside.
20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
AudioEye sits in a useful corner of software: websites and mobile apps keep needing accessibility testing, monitoring and remediation. The appeal is $41.2 million of ARR, about 78% GAAP gross margin and positive operating cash flow. The catch is that AEYE is s
AES has a large clean-power and utility platform, but the March 2026 $15.00 cash merger agreement changes the public-equity question into a regulatory-close trade backed by a company-disclosed growth-capital problem.
AEP has turned the utility growth story into a transmission-led data-center and industrial load story, lifting its 2026-2030 capital plan to $78 billion while preserving 2026 guidance. The investment case now depends on rate recovery, balance-sheet funding and
Acme United looks like a sleepy tools business until the filing mix shows first aid at roughly two-thirds of sales, a new My Medic deal, tariff pain, rising debt, and a customer-concentration test.
Official-source baseline for Able View Global using SEC submissions, SEC company facts, the FY2025 Form 20-F, H1 2025 Form 6-K interim statements, December 2025 and March 2026 Forms 6-K, and official peer filings.